BIMAGRUMAB
Biological
Novartis Pharmaceuticals Corporation
Total Payments
$6.0M
Transactions
166
Doctors
10
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $17,993 | 5 | 0 |
| 2019 | $889,928 | 29 | 3 |
| 2018 | $2.9M | 48 | 7 |
| 2017 | $2.2M | 84 | 10 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.0M | 166 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED STUDY TO ASSESS THE SAFETY PHARMACOKINETICS AND EFFICACY OF INTRAVENOUS BIMAGRUMAB IN OBESE PATIENTS WITH TYPE 2 DIABETES | Novartis Pharmaceuticals Corporation | $2.3M | 2 |
| A 28 WEEK RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTI CENTER PARALLEL GROUP DOSE RANGE FINDING STUDY TO ASSESS THE EFFECT OF MONTHLY DOSES OF BIMAGRUMAB 70 210 AND 700 MG ON SKELETAL MUSCLE STRENGTH AND FUNCTION IN OLDER ADULTS WITH SARCOPENIA | Novartis Pharmaceuticals Corporation | $1.7M | 0 |
| A 28 WEEK RANDOMIZED WITHDRAWAL EXTENSION OF A DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO ASSESS DURABILITY OF EFFECT ON SKELETAL MUSCLE STRENGTH AND FUNCTION UPON WITHDRAWAL OF BIMAGRUMAB 70 210 700 MG IN OLDER ADULTS WITH SARCOPENIA | Novartis Pharmaceuticals Corporation | $637,262 | 1 |
| A RANDOMIZED MULTI CENTRE DOUBLE BLIND PLACEBO CONTROLLED PHASE IIB TO EVALUATE THE SAFETY AND EFFICACY OF IV BYM338 ON FUNCTION MOBILITY AND FALL REDUCTION IN PATIENTS AFTER SURGICAL TREATMENT OF HIP FRACTURE | Novartis Pharmaceuticals Corporation | $557,003 | 1 |
| A 28 WEEK RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTI CENTER PARALLEL GROUP DOSE RANGE FINDING STUDY TO ASSESS THE EFFECT OF MONTHLY DOSES OF BIMAGRUMAB 70 210 AND 700 MG ON SKELETAL MUSCLE STRENGTH AND FUNCTION IN OLDER ADULTS WITH SARCOPENIA | NOVARTIS PHARMACEUTICALS CORPORATION | $227,679 | 6 |
| EXTENSION OF THE CBYM338B2203 PHASE IIB AND OR III STUDY TO EVALUATE THE LONG TERM EFFICACY SAFETY AND TOLERABILITY OF INTRAVENOUS BYM338 IN PATIENTS WITH SPORADIC INCLUSION BODY MYOSITIS | Novartis Pharmaceuticals Corporation | $218,650 | 0 |
| RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED DOSE FINDING STUDY TO EVALUATE EFFICACY SAFETY TOLERABILITY OF IV BYM338 AT 52 WEEKS ON PHYSICAL FUNCTION MUSCLE STRENGTH AND MOBILITY IN SPORADIC INCLUSION BODY MYOSITIS PATIENTS | Novartis Pharmaceuticals Corporation | $91,508 | 0 |
| AN EXPLORATORY RANDOMIZED PLACEBO CONTROLLED MULTIPLE DOSE STUDY TO EVALUATE SAFETY AND TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF DIFFERENT DOSING REGIMEN OF BIMAGRUMAB FOLLOWING SUBCUTANEOUS AND INTRAVENOUS ADMINISTRATIONS IN STABLE ELDERLY SUBJECTS | Novartis Pharmaceuticals Corporation | $63,728 | 0 |
| LARGE PROSPECTIVE NATURAL HISTORY TRIAL IN SIBM PATIENTS | Novartis Pharmaceuticals Corporation | $48,307 | 0 |
| A RANDOMIZED MULTI CENTRE DOUBLE BLIND PLACEBO CONTROLLED PHASE IIB TO EVALUATE THE SAFETY AND EFFICACY OF IV BYM338 ON FUNCTION MOBILITY AND FALL REDUCTION IN PATIENTS AFTER SURGICAL TREATMENT OF HIP FRACTURE | NOVARTIS PHARMACEUTICALS CORPORATION | $47,453 | 6 |
| AN OPEN LABEL LONG TERM STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF BYM338 IN PATIENTS WITH SPORADIC INCLUSION BODY MYOSITIS | Novartis Pharmaceuticals Corporation | $32,614 | 0 |
| A RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED STUDY TO ASSESS THE SAFETY PHARMACOKINETICS AND EFFICACY OF INTRAVENOUS BIMAGRUMAB IN OBESE PATIENTS WITH TYPE 2 DIABETES | NOVARTIS PHARMACEUTICALS CORPORATION | $17,489 | 2 |
| AN OPEN LABEL LONG TERM STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF BYM338 IN PATIENTS WITH SPORADIC INCLUSION BODY MYOSITIS | NOVARTIS PHARMACEUTICALS CORPORATION | $7,975 | 3 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $6,463 | 2 |
| A 28 WEEK RANDOMIZED WITHDRAWAL EXTENSION OF A DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO ASSESS DURABILITY OF EFFECT ON SKELETAL MUSCLE STRENGTH AND FUNCTION UPON WITHDRAWAL OF BIMAGRUMAB 70 210 700 MG IN OLDER ADULTS WITH SARCOPENIA | NOVARTIS PHARMACEUTICALS CORPORATION | $2,763 | 3 |
| LARGE PROSPECTIVE NATURAL HISTORY TRIAL IN SIBM PATIENTS | NOVARTIS PHARMACEUTICALS CORPORATION | $1,995 | 1 |
Top Doctors Receiving Payments for BIMAGRUMAB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Farmington, CT | $5.9M | 127 |
| , M.D | Cardiovascular Disease | Rochester, NY | $23,188 | 6 |
| , MD | Diagnostic Radiology | Rochester, NY | $22,965 | 11 |
| , MD | Specialist | Cape Coral, FL | $11,651 | 3 |
| , MD | Cardiovascular Disease | Rochester, NY | $10,625 | 5 |
| , MD | Cardiovascular Disease | Rochester, NY | $10,188 | 6 |
| , MD | Diagnostic Radiology | Rochester, NY | $7,088 | 2 |
| , M.D | Diagnostic Radiology | Rochester, NY | $6,592 | 3 |
| , MD | Neurology | Boston, MA | $3,770 | 1 |
| , MD | Geriatric Medicine | New Haven, CT | $2,693 | 1 |
| Steven Herbert | — | Rochester, NY | $132.50 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $6.0M
- Total Doctors 10
- Transactions 166
About BIMAGRUMAB
BIMAGRUMAB is a biological associated with $6.0M in payments to 10 healthcare providers, recorded across 166 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $17,993 was paid across 5 transactions to 0 doctors.
The most common payment nature for BIMAGRUMAB is "Unspecified" ($6.0M, 100.0% of total).
BIMAGRUMAB is associated with 16 research studies, including "A RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED STUDY TO ASSESS THE SAFETY PHARMACOKINETICS AND EFFICACY OF INTRAVENOUS BIMAGRUMAB IN OBESE PATIENTS WITH TYPE 2 DIABETES" ($2.3M).